Cardiovascular
Cardiovascular outcomes, heart failure, cardio-renal protection, hypertension, and lipid-lowering trials in diabetes and endocrinology.
Is a Family Lifestyle Program Cost-Effective for Heart Health?
A within-trial analysis of the PROLIFIC RCT finds a family-based lifestyle programme cost-effective for cardiovascular risk reduction in relatives of premature CHD patients. PICO summary and commentary.
Does Curcumin Help Diabetes and Heart Health?
An RCT finds curcumin lowers blood pressure, LDL, and inflammatory markers in type 2 diabetes but does not change HbA1c or glucose. PICO summary and expert commentary.
Adding Spironolactone to Dapagliflozin in HFmrEF/HFpEF: A Modest NT-proBNP Signal (SOGALDI-PEF)
In the SOGALDI-PEF crossover trial, adding spironolactone to dapagliflozin produced a modest 11% NT-proBNP reduction in HFmrEF/HFpEF, offset by eGFR decline and higher potassium. PICO summary and expert commentary.
Statin Plus PCSK9 Inhibitor Combination Achieves Greater Plaque Regression Than Either Alone: IVUS Study
A small IVUS study finds statin plus PCSK9 inhibitor drives greater plaque regression than either alone in borderline coronary lesions. PICO summary and expert commentary.
Can Statins Help Treat Diabetic Macular Edema?
A small RCT suggests low-dose atorvastatin may aid anti-VEGF therapy for diabetic macular edema more than high-dose, though key endpoints were non-significant. PICO summary and commentary.
Should Blood Pressure Be Tightly Controlled After Stroke in Diabetics?
A post-hoc ACCORD-BP analysis links intensive blood pressure control to lower cardiovascular events in diabetics with prior stroke, without raising recurrent stroke. PICO summary and commentary.
Does Semaglutide Improve Lipid Profiles in Type 2 Diabetes?
A small 52-week single-centre randomised trial found once-weekly semaglutide shifted lipoprotein subfractions toward a less atherogenic profile versus sitagliptin in type 2 diabetes. PICO summary and expert commentary.
Do SGLT2 Inhibitors Reduce Myocardial Fibrosis in Diabetic HFpEF?
A double-blind randomised trial of dapagliflozin versus placebo for myocardial fibrosis on cardiac MRI in 100 patients with type 2 diabetes and HFpEF. PICO summary and expert commentary.
Exenatide Plus Glucagon Co-Infusion Increases Myocardial Glucose Uptake and Improves Diastolic Function in Type 2 Diabetes
A small mechanistic study finds exenatide plus glucagon doubles myocardial glucose uptake in type 2 diabetes, a proof-of-concept for cardiac metabolic effects. PICO summary and commentary.